263 related articles for article (PubMed ID: 8942453)
1. Individual variation in D2 dopamine receptor occupancy in clozapine-treated patients.
Pickar D; Su TP; Weinberger DR; Coppola R; Malhotra AK; Knable MB; Lee KS; Gorey J; Bartko JJ; Breier A; Hsiao J
Am J Psychiatry; 1996 Dec; 153(12):1571-8. PubMed ID: 8942453
[TBL] [Abstract][Full Text] [Related]
2. In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol.
Tauscher J; Küfferle B; Asenbaum S; Fischer P; Pezawas L; Barnas C; Tauscher-Wisniewski S; Brücke T; Kasper S
Psychopharmacology (Berl); 1999 Jan; 141(2):175-81. PubMed ID: 9952042
[TBL] [Abstract][Full Text] [Related]
3. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
Dresel S; Tatsch K; Dähne I; Mager T; Scherer J; Hahn K
J Nucl Med; 1998 Jul; 39(7):1138-42. PubMed ID: 9669383
[TBL] [Abstract][Full Text] [Related]
4. [123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics.
Klemm E; Grünwald F; Kasper S; Menzel C; Broich K; Danos P; Reichmann K; Krappel C; Rieker O; Briele B; Hotze AL; Möller HJ; Biersack HJ
Am J Psychiatry; 1996 Feb; 153(2):183-90. PubMed ID: 8561197
[TBL] [Abstract][Full Text] [Related]
5. The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia.
Gründer G; Landvogt C; Vernaleken I; Buchholz HG; Ondracek J; Siessmeier T; Härtter S; Schreckenberger M; Stoeter P; Hiemke C; Rösch F; Wong DF; Bartenstein P
Neuropsychopharmacology; 2006 May; 31(5):1027-35. PubMed ID: 16237387
[TBL] [Abstract][Full Text] [Related]
6. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
[TBL] [Abstract][Full Text] [Related]
7. Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study.
Pilowsky LS; Busatto GF; Taylor M; Costa DC; Sharma T; Sigmundsson T; Ell PJ; Nohria V; Kerwin RW
Psychopharmacology (Berl); 1996 Mar; 124(1-2):148-53. PubMed ID: 8935810
[TBL] [Abstract][Full Text] [Related]
8. Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas.
Vernaleken I; Janouschek H; Raptis M; Hellmann S; Veselinovic T; Bröcheler A; Boy C; Cumming P; Hiemke C; Rösch F; Schäfer WM; Gründer G
Int J Neuropsychopharmacol; 2010 Aug; 13(7):951-60. PubMed ID: 20392299
[TBL] [Abstract][Full Text] [Related]
9. D2-dopamine receptor occupancy measured by IBZM-SPECT in relation to extrapyramidal side effects.
Broich K; Grünwald F; Kasper S; Klemm E; Biersack HJ; Möller HJ
Pharmacopsychiatry; 1998 Sep; 31(5):159-62. PubMed ID: 9832346
[TBL] [Abstract][Full Text] [Related]
10. A single photon emission computed tomography scan study of striatal dopamine D2 receptor binding with 123I-epidepride in patients with schizophrenia and controls.
Tibbo P; Silverstone PH; McEwan AJ; Scott J; Joshua A; Golberg K
J Psychiatry Neurosci; 1997 Jan; 22(1):39-45. PubMed ID: 9002391
[TBL] [Abstract][Full Text] [Related]
11. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.
Kegeles LS; Slifstein M; Frankle WG; Xu X; Hackett E; Bae SA; Gonzales R; Kim JH; Alvarez B; Gil R; Laruelle M; Abi-Dargham A
Neuropsychopharmacology; 2008 Dec; 33(13):3111-25. PubMed ID: 18418366
[TBL] [Abstract][Full Text] [Related]
12. Prolactin plasma levels and D2-dopamine receptor occupancy measured with IBZM-SPECT.
Schlegel S; Schlösser R; Hiemke C; Nickel O; Bockisch A; Hahn K
Psychopharmacology (Berl); 1996 Apr; 124(3):285-7. PubMed ID: 8740053
[TBL] [Abstract][Full Text] [Related]
13. Striatal D2/D3 receptor occupancy, clinical response and side effects with amisulpride: an iodine-123-iodobenzamide SPET study.
Meisenzahl EM; Schmitt G; Gründer G; Dresel S; Frodl T; la Fougère C; Scheuerecker J; Schwarz M; Boerner R; Stauss J; Hahn K; Möller HJ
Pharmacopsychiatry; 2008 Sep; 41(5):169-75. PubMed ID: 18763218
[TBL] [Abstract][Full Text] [Related]
14. Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol - a 123I-IBZM SPECT study.
Kasper S; Tauscher J; Küfferle B; Barnas C; Hesselmann B; Asenbaum S; Podreka I; Brücke T
Psychopharmacology (Berl); 1998 Apr; 136(4):367-73. PubMed ID: 9600582
[TBL] [Abstract][Full Text] [Related]
15. The prognostic value of dopamine receptor occupancy by [123I]IBZM-SPECT in schizophrenic patients treated with quetiapine.
Pávics L; Szekeres G; Ambrus E; Kéri S; Kovács Z; Argyelán M; Kanyó B; Csernay L; Janka Z
Nucl Med Rev Cent East Eur; 2004; 7(2):129-33. PubMed ID: 15968599
[TBL] [Abstract][Full Text] [Related]
16. Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796.
Seibyl JP; Zea-Ponce Y; Brenner L; Baldwin RM; Krystal JH; Offord SJ; Mochoviak S; Charney DS; Hoffer PB; Innis RB
J Nucl Med; 1996 Jan; 37(1):11-5. PubMed ID: 8543979
[TBL] [Abstract][Full Text] [Related]
17. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study.
Bigliani V; Mulligan RS; Acton PD; Ohlsen RI; Pike VW; Ell PJ; Gacinovic S; Kerwin RW; Pilowsky LS
Psychopharmacology (Berl); 2000 Jun; 150(2):132-40. PubMed ID: 10907666
[TBL] [Abstract][Full Text] [Related]
18. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.
Bressan RA; Erlandsson K; Jones HM; Mulligan R; Flanagan RJ; Ell PJ; Pilowsky LS
Am J Psychiatry; 2003 Aug; 160(8):1413-20. PubMed ID: 12900302
[TBL] [Abstract][Full Text] [Related]
19. Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint.
Bernardo M; Parellada E; Lomeña F; Catafau AM; Font M; Gómez JC; López-Carrero C; Gutiérrez F; Pavía J; Salamero M
Psychiatry Res; 2001 Aug; 107(2):87-97. PubMed ID: 11530275
[TBL] [Abstract][Full Text] [Related]
20. IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol.
Küfferle B; Tauscher J; Asenbaum S; Vesely C; Podreka I; Brücke T; Kasper S
Psychopharmacology (Berl); 1997 Oct; 133(4):323-8. PubMed ID: 9372530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
